普外科手术治疗终末期肝病的临床疗效及安全性评价

摘要

Objective To observe the clinical effectiveness and safety of general surgical treatment of end-stage liver disease.Methods One hundred and two patients with end-stage liver disease were selected,patients underwent stem cell transplantation were assigned to group A (67 cases),patients didn't underwent stem cell transplantation were assigned to group B (35 cases).In 2,4,8,12,24 weeks after treatment,followed up and recorded changes of serum ALB,PTA,CHE,TBil and the clinical symptom scores and other indicators.The prognosis and complications were compared between the two groups,the effect and safety of the operation was evaluated.Results Followed up for 2,4,8,12 and 24 weeks,the changes of serum TBil had no statistical significance (P>0.05);Followed up for 2 weeks,the changes of serum ALB,PTA,CHE between the two groups had no statistical significance (P>0.05);Followed up for 4,8,12 and 24 weeks,the changes of serum ALB,PTA,CHE between the two groups had statistical significance differences (P<0.01);Followed up for 4,12 and 24 weeks,the clinical symptom score changes between the two groups had statistical significance differences(P<0.05 or P<0.01);the incidence of complications and prognosis between the two groups had no statistically significant difference(P>0.05).Conclusions General surgical treatment in patients with end-stage liver disease can significantly improve the serum level of ALB,PTA,CHE,and improve the clinical symptoms of patients.%目的 观察普外科手术治疗终末期肝病的临床疗效及安全性.方法 对102例终末期肝病患者进行分析,行干细胞移植术者归为A组(67例),未行干细胞移植术者归为B组(35例),于治疗后2、4、8、12、24周随访记录两组患者的血清白蛋白(ALB)、凝血酶原活动度(PTA)、胆碱酯酶(CHE)、总胆红素(TBiL)、临床症状评分等指标的变化情况,进行组间协方差比较,对预后情况及并发症进行对比,评价手术的疗效及安全性.结果 随访2、4、8、12、24周,两组患者血清TBiL变化比较差异未见统计学意义(P>0.05);随访2周后血清ALB、PTA、CHE变化情况组间协方差比较差异未见统计学意义(P>0.05);随访4、8、12、24周两组患者血清ALB、PTA、CHE变化组间比较差异有统计学意义(P<0.01);随访4周,两组临床症状评分变化比较差异有统计学意义(P<0.05),随访12、24周组间比较差异有统计学意义(P<0.01);两组并发症发生率比较差异未见统计学意义(P>0.05).结论 普外科手术治疗终末期肝病能显著提高患者的ALB、PTA、CHE水平,改善患者的临床症状.